Theravance, Merck partner to develop cardiovascular therapeutics
As per the agreement, Merck will gain exclusive license to Theravance’s therapeutic candidates and will in return make $5m upfront payment, funding to carryout research activites. Theravance is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.